Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin.

Novo has identified glucose-sensitive insulin

Read the full 284 word article

User Sign In